Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 8/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561897 | 0.78 | CCR2 (0.40) | CETPADORA1PARP1P2RX7NPY2R | |
| SCHEMBL3260122 | 0.77 | CETP (0.39) | CETPADORA1PARP1P2RX7NPY2R | |
| SCHEMBL3565829 | 0.71 | CCR2 (0.34) | CETPADORA1NPY2RROCK1CYP3A4 | |
| SCHEMBL11120380 | 0.64 | KMT2A (0.48) | CETPPARP1P2RX7LMNA | |
| SCHEMBL15505954 | 0.62 | CETP (0.44) | CETPP2RX7LMNAGAACRHBP | |
| SCHEMBL29770386 | 0.62 | NR2E3 (0.41) | CETPADORA1LMNAGAA | |
| SCHEMBL27203377 | 0.62 | NR2E3 (0.41) | CETPADORA1LMNAGAA | |
| SCHEMBL11117692 | 0.62 | KMT2A (0.48) | PARP1P2RX7LMNA | |
| SCHEMBL31506275 | 0.61 | CETP (0.61) | CETPP2RX7LMNA | |
| SCHEMBL2034401 | 0.61 | CETP (0.47) | CETPP2RX7NPY2RCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | CETP 2387/4885ADORA1 549/4885PARP1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.